Deslanoside

Intravenous
Cardiac arrhythmias, Heart failure

Wolff-Parkinson-White syndrome; hypertrophic obstructive cardiomyopathy.

CV disease; partial heart block, sinus node disorders, acute myocarditis, acute MI, advanced heart failure, severe pulmonary disease, thyroid dysfunction, hypokalaemia, hypomagnesaemia, hypercalcaemia, hypoxia, hypothyroidism, impaired renal function, elderly, premature infants. Maintain heart rate >60 beats/min. withdraw 1-2 days before undergoing cardioversion. Not an appropriate form of therapy for any ventricular arrhythmia. Pregnancy.

Nausea, vomiting, anorexia, diarrhoea, abdominal pain, headache, facial pain, fatigue, weakness, dizziness, drowsiness, disorientation, mental confusion, bad dreams, delirium, acute psychoses, hallucinations, convulsions, blurred vision, color vision may be affected, gynecomastia, vasoconstriction, and transient hypotension (rapid IV inj), local irritation (SC/IM), hypokalaemia.
Potentially Fatal: Heart failure, supraventricular or ventricular arrhythmias, defects of conduction.

Thiazides, loop diuretics; corticosteroids; β₂-agonist, amphotericin B; sodium polystyrene sulfonate; carbenoxolone; IV admin of calcium salts; quinidine; amiodarone; propafenone; other antiarrhythmics; β-blockers; calcium-channel blockers.

Description:
Mechanism of Action: Deslanoside is a cardiac glycoside with positive inotropic activity.
Onset: 5-10 min.
Duration: 2-5 days.
Pharmacokinetics:
Absorption: Effects occur within 5-10 min after IV admin.
Excretion: Half-life: About 33 hr.

Cardiac Drugs